Thursday, January 27, 2022   fundraising

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led...

fundraising

Thursday, January 27, 2022

Ractigen Therapeutics closes an additional $30 million in Series A+ funding to push development of its RNAa platform

[01/27/2022, Nantong] Ractigen Therapeutics today announced the closing of a Series A+ financing round totaling $30 million led by SDIC Venture Capital with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, and Xianghe Capital.